As idiopathic pulmonary fibrosis emerges as an important public health problem, there is a
need to coordinate data on incidence and mortality globally. This study aims to …

The world's population is ageing and an important part of this demographic shift is the
development of chronic illness. In short, a person who does not die of acute illnesses, such …

Background Published data for the epidemiology of idiopathic pulmonary fibrosis in the USA
are scarce. We sought to estimate the incidence, prevalence, and mortality risk of idiopathic …

Mesenchymal stromal/stem cell (MSC) therapy has shown promise in experimental models
of idiopathic pulmonary fibrosis (IPF). The aim of this study was to test the therapeutic effects …

Idiopathic pulmonary fibrosis (IPF) is a rare disease, with estimates of prevalence varying
considerably across countries due to paucity in data collection. The aim of this study was to …

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a median survival time
from diagnosis of 2–3 years. Although the pathogenic pathways have not been fully …

Rationale: Estimates of idiopathic pulmonary fibrosis (IPF) incidence and prevalence from
electronic databases without case validation may be inaccurate. Objectives: Develop claims …

Abstract Background Interstitial lung diseases (ILDs) are a heterogeneous group of diseases
characterized by widespread fibrotic and inflammatory abnormalities of the lung. Respiratory …

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial
pneumonias and is characterised by progressive accumulation of scar tissue in the lungs …

OVERVIEW OF IPF AND EVIDENCE-BASED GUIDELINES of patients with a radiographic
and histopathologic pattern of usual interstitial pneumonia (UIP) and no other identifiable …